Related news from
Wed, 08 May 2024 10:06:15 +0000	Q1 2024 Pulse Biosciences Inc Earnings Call Q1 2024 Pulse Biosciences Inc Earnings Call
Wed, 08 May 2024 07:56:41 +0000	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... Insights into Pulse Biosciences' operational advancements, FDA clearances, and financial strategies shaping its Q1 2024 outcomes.
Tue, 07 May 2024 21:45:34 +0000	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments Increased R&D Expenses and Strategic Investments Mark the Quarter
Tue, 07 May 2024 20:05:00 +0000	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results HAYWARD, Calif., May 07, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024.
Thu, 02 May 2024 12:00:00 +0000	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 HAYWARD, Calif., May 02, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has set the record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock"), as of
Wed, 24 Apr 2024 20:05:00 +0000	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 HAYWARD, Calif., April 24, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
Mon, 01 Apr 2024 20:19:51 +0000	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript March 28, 2024 Pulse Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Pulse Biosciences Fourth Quarter 2023 Earnings Conference Call. At this time, all […]
Fri, 29 Mar 2024 10:30:29 +0000	Q4 2023 Pulse Biosciences Inc Earnings Call Q4 2023 Pulse Biosciences Inc Earnings Call
Thu, 28 Mar 2024 21:51:44 +0000	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 Financial Highlights Reflect Development Progress and Cost Management
Thu, 28 Mar 2024 20:12:00 +0000	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results HAYWARD, Calif., March 28, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.
Thu, 28 Mar 2024 20:10:00 +0000	Pulse Biosciences Announces Plans to Initiate a Rights Offering HAYWARD, Calif., March 28, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering.
Thu, 14 Mar 2024 20:05:00 +0000	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 HAYWARD, Calif., March 14, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, March 28, 2024. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
Fri, 08 Mar 2024 18:17:00 +0000	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System HAYWARD, Calif., March 08, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its novel CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures.
Wed, 14 Feb 2024 13:00:00 +0000	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study HAYWARD, Calif., February 14, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced favorable findings from the 60-day post-procedure evaluations for four initial patients treated in the Company’s CellFX® nsPFA™ 360° Cardiac Catheter First-In-Human Feasibility Study.
Fri, 02 Feb 2024 14:53:26 +0000	Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth We can readily understand why investors are attracted to unprofitable companies. By way of example, Pulse Biosciences...
Wed, 31 Jan 2024 13:00:00 +0000	Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium HAYWARD, Calif., January 31, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field (nsPFA) technology for the treatment of atrial fibrillation, today announced that its nsPFA technology will be featured in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts, on February 2, 2024 at 10:00am ET.
Sat, 06 Jan 2024 14:01:02 +0000	Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion The...
Tue, 02 Jan 2024 13:00:00 +0000	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp HAYWARD, Calif., January 02, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA Cardiac Clamp.
Wed, 20 Dec 2023 13:00:00 +0000	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter HAYWARD, Calif., December 20, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and
Sun, 03 Dec 2023 12:09:39 +0000	Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock Pulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders (or potential shareholders) will be happy to see that the...